Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome

NCT05137496 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Macrophage Activation Syndrome

Interventions

DRUG: Ruxolitinib
DRUG: methylprednisolone

Sponsor

Beijing Friendship Hospital